Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants positive opinion for orphan drug status for enadenotucirev

Jan. 14, 2015

EMA accepts alirocumab MAA for review

Jan. 12, 2015

Celgene receives positive CHMP opinion to extend Revlimid indication

Dec. 24, 2014

EMA committee recommends approval of dalbavancin

Dec. 24, 2014

Xiapex receives positive opinion by CHMP for Peyronie's disease

Dec. 23, 2014

CHMP backs approval of Orexigen's naltrexone/bupropion for weight management

Dec. 22, 2014

EMA committee recommends approval of Xadago to treat mid- to late-stage Parkinson's disease

Dec. 22, 2014

Polaris' ADI-PEG20 receives E.U. orphan drug status for MPM

Dec. 22, 2014

CCX-168 receives European orphan designation for ANCA-associated vasculitis

Dec. 9, 2014

EMA determines no evidence that Fluad caused deaths in Italy

Dec. 9, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...